1. Tuli, H.S., R. Joshi, G. Kaur, V.K. Garg and K. Sak et al., 2023. Metal nanoparticles in cancer: From synthesis and metabolism to cellular interactions. J. Nanostruct. Chem., 13: 321-348.
   CrossRef  |  Direct Link  |  
2. Tuli, H.S., J. Kaur, K. Vashishth, K. Sak and U. Sharma et al., 2023. Molecular mechanisms behind ROS regulation in cancer: A balancing act between augmented tumorigenesis and cell apoptosis. Arch. Toxicol., 97: 103-120.
   CrossRef  |  Direct Link  |  
3. Varol, A., S. Sezen, D. Evcimen, A. Zarepour and G. Ulus et al., 2022. Cellular targets and molecular activity mechanisms of bee venom in cancer: Recent trends and developments. Toxin Rev., 41: 1382-1395.
   CrossRef  |  Direct Link  |  
4. Tuli, H.S., V.K. Garg, J.K. Mehta, G. Kaur and R.K. Mohapatra et al., 2022. Licorice (Glycyrrhiza glabra L.)-derived phytochemicals target multiple signaling pathways to confer oncopreventive and oncotherapeutic effects. OncoTargets Ther., 15: 1419-1448.
   CrossRef  |  Direct Link  |  
5. Tuli, H.S., P. Rath, A. Chauhan, S. Ramniwas and K. Vashishth et al., 2022. Phloretin, as a potent anticancer compound: From chemistry to cellular interactions. Molecules, Vol. 27. 10.3390/molecules27248819.
   CrossRef  |  Direct Link  |  
6. Tuli, H.S., K. Sak, A. Iqubal, V.K. Garg and M. Varol et al., 2022. STAT signaling as a target for intervention: From cancer inflammation and angiogenesis to non-coding RNAs modulation. Mol. Biol. Rep., 49: 8987-8999.
   CrossRef  |  Direct Link  |  
7. Tuli, H.S., A. Kumar, K. Sak, D. Aggarwal and D.S. Gupta et al., 2022. Gut microbiota-assisted synthesis, cellular interactions and synergistic perspectives of equol as a potent anticancer isoflavone. Pharmaceuticals, Vol. 15. 10.3390/ph15111418.
   CrossRef  |  Direct Link  |  
8. Kumar, M., P. Aggarwal, M. Varol, S. Sharma and A. Rani et al., 2022. Synthesis, spectral investigations, biological potential and molecular docking study of novel schiff base and its transition metal complexes. Anti-Infect. Agents, 20: 47-64.
   CrossRef  |  Direct Link  |  
9. Aggarwal, V., H.S. Tuli, M. Tania, S. Srivastava and E.E. Ritzer et al., 2022. Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement. Semi. Cancer Biol., 80: 256-275.
   CrossRef  |  Direct Link  |  
10. Abbas, Z., M. Kumar, H.S. Tuli, E.M. Janahi and Shafiul Haque et al., 2022. Synthesis, structural investigations, and in vitro/in silico bioactivities of flavonoid substituted biguanide: A novel schiff base and its diorganotin (IV) complexes. Molecules, Vol. 27. 10.3390/molecules27248874.
    CrossRef  |  Direct Link  |  
11. Abbas, Z., H.S. Tuli, M. Varol, S. Sharma, H.K. Sharma, P. Aggarwal and M. Kumar, 2022. Organotin (IV) complexes derived from Schiff base 1,3-bis[(1E)-1-(2-hydroxyphenyl)ethylidene] thiourea: Synthesis, spectral investigation and biological study to molecular docking. J. Iran. Chem. Soc., 19: 1923-1935.
    CrossRef  |  Direct Link  |  
12. Tuli, H.S., V. Aggarwal, M. Tuorkey, D. Aggarwal and N.C. Parashar et al., 2021. Emodin: A metabolite that exhibits anti-neoplastic activities by modulating multiple oncogenic targets. Toxicol. In Vitro, Vol. 73. 10.1016/j.tiv.2021.105142.
    CrossRef  |  Direct Link  |  
13. Tuli, H.S., V. Aggarwal, G. Parashar, D. Aggarwal and N.C. Parashar et al., 2021. Xanthohumol: A metabolite with promising anti-neoplastic potential. Anticancer Agents Med. Chem., 22: 418-432.
    CrossRef  |  Direct Link  |  
14. Tuli, H.S., S. Mittal, M. Loka, V. Aggarwal and D. Aggarwal et al., 2021. Deguelin targets multiple oncogenic signaling pathways to combat human malignancies. Pharm. Res., Vol. 166. 10.1016/j.phrs.2021.105487.
    CrossRef  |  Direct Link  |  
15. Tuli, H.S., S. Mittal, D. Aggarwal, G. Parashar and N.C. Parashar et al., 2021. Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. Semin. Cancer Biol., 73: 196-218.
    CrossRef  |  Direct Link  |  
16. Aggarwal, V., H.S. Tuli, M. Varol, M. Tuorkey and K. Sak et al., 2021. NOTCH signaling: Journey of an evolutionarily conserved pathway in driving tumor progression and its modulation as a therapeutic target. Crit. Rev. Oncol. Hematol., Vol. 164. 10.1016/j.critrevonc.2021.103403.
    CrossRef  |  Direct Link  |